Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated to proteinaceous toxin or fragment thereof
Reexamination Certificate
2006-10-24
2006-10-24
Duffy, Patricia A. (Department: 1645)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated to proteinaceous toxin or fragment thereof
C424S181100, C530S391700
Reexamination Certificate
active
07125554
ABSTRACT:
The present invention relates to compositions and methods of use, wherein the composition comprises a conjugate of a bacterial superantigen and an antibody moiety. More particularly, the bacterial superantigen has been modified to decrease seroreactivity with retained superantigen activity.
REFERENCES:
patent: 5519114 (1996-05-01), Johnson et al.
patent: 5545716 (1996-08-01), Johnson et al.
patent: 5728388 (1998-03-01), Terman
patent: 5858363 (1999-01-01), Dohlsten et al.
patent: 5859207 (1999-01-01), Johnson et al.
patent: 6042837 (2000-03-01), Kalland et al.
patent: 6126945 (2000-10-01), Terman et al.
patent: 6180097 (2001-01-01), Terman
patent: 6197299 (2001-03-01), Dohlsten et al.
patent: 6221351 (2001-04-01), Terman
patent: 6251385 (2001-06-01), Terman
patent: 6338845 (2002-01-01), Terman
patent: 6340461 (2002-01-01), Terman
patent: 6399332 (2002-06-01), Ulrich et al.
patent: 6447777 (2002-09-01), Terman et al.
patent: 6514498 (2003-02-01), Antonsson et al.
patent: 6632441 (2003-10-01), Schlievert et al.
patent: 6632640 (2003-10-01), Lee et al.
patent: 6692746 (2004-02-01), Terman et al.
patent: 6713284 (2004-03-01), Ulrich et al.
patent: 2001/0046501 (2001-11-01), Johnson et al.
patent: 2002/0018781 (2002-02-01), Schlievert et al.
patent: 2002/0028211 (2002-03-01), Kaempfer et al.
patent: 2002/0039585 (2002-04-01), Schlievert et al.
patent: 2002/0051765 (2002-05-01), Terman
patent: 2002/0058032 (2002-05-01), Hirai et al.
patent: 2002/0086813 (2002-07-01), Schlievert et al.
patent: 2002/0115190 (2002-08-01), Chen
patent: 2002/0141981 (2002-10-01), Lawman et al.
patent: 2002/0177551 (2002-11-01), Terman
patent: 2003/0009015 (2003-01-01), Ulrich et al.
patent: 2003/0036644 (2003-02-01), Ulrich et al.
patent: 2003/0039655 (2003-02-01), Forsberg et al.
patent: 2003/0092894 (2003-05-01), Antonsson et al.
patent: 2003/0124142 (2003-07-01), Fraser et al.
patent: 2003/0157113 (2003-08-01), Terman
patent: 2004/0142464 (2004-07-01), Lawman et al.
patent: WO-96/01650 (1996-01-01), None
patent: WO-96/36366 (1996-11-01), None
patent: 97/36932 (1997-10-01), None
patent: WO-97/36932 (1997-10-01), None
patent: WO-9736032 (1997-10-01), None
patent: WO-99/04820 (1999-02-01), None
patent: WO-01/30854 (2001-05-01), None
patent: WO-01/36486 (2001-05-01), None
Weinrauch, Y. Annual Review of Microbiology 53:155-87, 1999.
Sundström, M. et al. The co-crystal of staphylococcal enterotoxin type A with Zn2at 2.7 ÅResolution; The Journal of Biological Chemistry; vol. 271 No. 50, 1996 pp. 32212-32216.
Sundström, Michael et al. The crystal structure of staphylococcal enterotoxin type D reveals Zn2+-mediated homodimerization; The EMBO Journal vol. 15, No. 24, pp. 6832-6840, 1996.
Schad, E.M. et al., Crystal structure of the superantigen staphylococcal enterotoxin type A; The EMBO Journal vol. 14, No. 14, pp. 3292-3301, 1995.
Papageorgiou, A. Microbial superantigens: from structure to function; Trends in Microbiology, vol. 8, No. 8, pp. 369-375, 2000.
Håkansson, M. et al., The Crystal Structure of Staphylococcal Enterotoxin H: Implications for Binding Properties to MHC Class II and TcR Molecules; J. Mol. Biol. 2000; 302, 527-537.
Dohlsten, M. et al., Monoclonal antibody-superantigen fusion proteins: Tumor-specific agents for T-cell based tumor therapy; Proc. Natl. Acad. Sci. USA 1994; vol. 91, pp. 8945-8949.
Cavallin, A. et al., The spectral and thermodynamic properties of staphylococcal enterotoxin A, E, and variants suggest that structural modifications are important to control their function; J. Biol Chemistry; 2000; vol. 275, No. 3, pp. 1665-1672.
Burks, E. et al., In vitro scanning saturation mutagenesis of an antibody binding pocket; Proc. Natl. Acad. Sci. USA, 1997. vol. 94, pp. 412-417.
Antonsson, P. et al. Functional characterization of the interaction between the superantigen staphylococcal enterotoxin A and the TCR; J. Immunology; 1997; pp. 4245-4251.
Alpaugh, R. K. et al., Superantigen-targeted Therapy: Phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies; Clinical Cancer Research 1998, Vo. 4 pp. 1903-1914.
Abrahamsen, L. et al., Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A; The EMBO Journal; 1995, v. 14, No. 13; pp. 2978-2786.
Griggs et al., “Mapping of Multiple Binding Domains of the Superantigen Staphylococcal Enterotoxin a for HLA,” Journal of Immunology vol. 148, 1992, pp. 2516-2521.
Sogaard et al., “Antibody-targeted Superantigens in Cancer Immunotherapy,” Immunotechnology 2, 1996, pp. 151-162.
Hansson et al., “Genetically Engineered Superantigens as Tolerable Antitumor Agents,” Proc. Natl. Acad. Sci. vol. 94, Mar. 1997, pp. 2489-2494.
Rosendahl et al, “Long-Term Survival and Complete Cures of B16 Melanoma-Carrying Animals After Therapy with Tumor-Targeted IL-2 and Sea,” Int. J. Cancer 81, 1999, pp. 156-163.
Forsberg et al., “Therapy of Human Non-small-cell lung Carcinoma Using Antibody Targeting of a Modified Superantigen,” British Journal of Cancer 85 (1), 2001, pp. 129-136.
Third Response to Written Opinion for PCT/SE 02/01188.
Preliminary Examination Report for PCT/SE 02/01188.
U.S. Appl. No. 09/463,470, filed Jan. 21, 2000.
Antonsson Per
Erlandsson Eva
Forsberg Goran
Walse Bjorn
Active Biotech AB
Duffy Patricia A.
Fulbright & Jaworski LLP
LandOfFree
Engineered superantigen for human therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Engineered superantigen for human therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Engineered superantigen for human therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3633044